Last reviewed · How we verify
CB-839 Capsules
At a glance
| Generic name | CB-839 Capsules |
|---|---|
| Also known as | Glutaminase inhibitor |
| Sponsor | Calithera Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (PHASE1, PHASE2)
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (PHASE1)
- Telaglenastat + Talazoparib In Prostate Cancer (PHASE2)
- Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors (PHASE1)
- Study of the Glutaminase Inhibitor CB-839 in Leukemia (PHASE1)
- A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |